{"id":"NCT01399125","sponsor":"Novartis Pharmaceuticals","briefTitle":"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","officialTitle":"A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-05","completion":"2013-05","firstPosted":"2011-07-21","resultsPosted":"2014-08-04","lastUpdate":"2014-08-04"},"enrollment":501,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Rivastigmine Patch","otherNames":["ENA713, Exelon"]},{"type":"DRUG","name":"Rivastigmine Capsules","otherNames":["ENA713, Exelon"]},{"type":"DRUG","name":"Placebo to Rivastigmine patch","otherNames":["placebo"]},{"type":"DRUG","name":"Placebo to Rivastigmine capsules","otherNames":["placebo"]}],"arms":[{"label":"Rivastigmine patch","type":"EXPERIMENTAL"},{"label":"Rivastigmine capsules","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon® patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory submission and registration of Exelon transdermal patch in China. The study is designed to confirm the non-inferiority of the efficacy of Exelon patch (target 10 cm² patch size) versus Exelon capsules (target 6.0 mg bid dose) on cognition, using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog).","primaryOutcome":{"measure":"Change From Baseline on Cognition, Assessed by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)","timeFrame":"Change at 24 weeks","effectByArm":[{"arm":"Rivastigmine Patch","deltaMin":-0.5,"sd":6.7},{"arm":"Rivastigmine Capsules","deltaMin":-0.7,"sd":6.74}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":16,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":247},"commonTop":["Decreased appetite","Nausea","Vomiting","Dizziness","Application site pruritus"]}}